HRMY News and Press, Harmony Biosciences Holdings Inc. From 04/11/24

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST TPM-1116 preclinical data suggest a potential best-in-class profile that could transform the treatment of narcolepsy and other sleep/wake...

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME Trial initiation a step toward potentially treating excessive daytime sleepiness and behavioral symptoms in patients with PWS PR Newswire ...

HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE PR Newswire PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will parti...

2024-03-18 14:07:39 ET Summary The healthcare sector is overvalued by about 13% relative to 11-year averages, but overvaluation varies a lot across subsectors. Healthcare equipment has the worst value and quality scores. iShares Global Healthcare ETF is a global alternative to...

2024-03-02 14:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-22 15:30:18 ET Image source: The Motley Fool. Harmony Biosciences (NASDAQ: HRMY) Q4 2023 Earnings Call Feb 22, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Harmony Biosciences (HRMY) Q4 2023 Earnings Call Tran...

2024-02-22 13:32:10 ET Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Results Conference Call February 22, 2024 08:30 AM ET Company Participants Luis Sanay - Head of Investor Relations Jeffrey Dayno - President and CEO Jeffrey Dierks - Chief Commercial Officer...

2024-02-21 10:48:52 ET More on Harmony Biosciences Harmony Biosciences: 4 Problems With Investing (Rating Downgrade) Harmony gets FDA orphan drug status for Prader-Willi treatment Harmony Biosciences says Q4 preliminary net product revenue was about $168M See...

2024-02-21 09:42:51 ET Major earnings expected before the bell on Thursday include: Dominion Energy ( D ) Iron Mountain ( IRM ) Moderna ( MRNA ) Newmont ( NEM ) Nikola ( NKLA ) Read the full article on Seeking Alpha For further details...

U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY PR Newswire Prescription Drug User Fee Act date is June 21, 2024 PLYMOUTH MEETING, Pa. , Feb. 21, 2024 /PRNewswire/ -...